Abstract

A RETROSPECTIVE OBSERVATIONAL STUDY ON CASES OF SARCOMA TREATED WITH THE DI BELLA METHOD: RATIONALE AND EFFECTIVENESS

Giuseppe Di Bella*, Vittoria Borghetto, Ilaria Moscato and Elena Costanzo

Abstract

Despite all the new developments in cancer therapy, the life expectancy of patients with sarcoma remains short. Since it was established as a cancer therapy, the Di Bella Method (DBM) has been able to increase survival rate and life quality, without overt toxicity, in comparison to what is described in the literature for the treatment of sarcoma with the same immunohistochemical, histologic and clinical features. We therefore treated 37 patients with sarcoma using the DBM protocol. The DBM therapy consists of somatostatin and analogues (octreotide), all trans-retinoic acid (ATRA), β-Carotene, axerophthol dissolved in vitamin E, vitamin D, vitamin C, melatonin (MLT), proteoglycans, glycosaminoglycans, hydroxyurea, Sodium butyrate (Na-Bu). These molecules have antiproliferative, antiangiogenic, cytostatic, antioxidant, antimetastatic (differentiative) and immunomodulating properties. Moreover, the inclusion of ATRA, MLT and Na-Bu has increased the antitumoral properties of the therapy by extending them to cancer stem cells. Furthermore, the non-cytolytic and non-cytotoxic metronomic dosage of hydroxyurea has improved the outcome of DBM therapy by increasing anti-tumour capability. The results of this treatment revealed the effectiveness of the DBM. In conclusion, the multi-strategic objectives of the DBM are to inhibit proliferation-invasiveness and neoplastic angiogenesis, silence the survival system of cancer stem cells, enhance immunomodulatory and antioxidant activities, improve the vitality and efficiency of normal cells, and depress the efficiency and vitality of neoplastic ones.

Keywords: Sarcoma; Growth Factor; Somatostatin; Melatonin; Retinoic Acid; Vitamin D; Vitamin E; Prolactin; Di Bella Method; D2 R agonists.